SRZN - Surrozen, Inc./DE
IEX Last Trade
11.915
0 0%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:09:47 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$11.92
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
15.85%
1 Month
34.65%
3 Months
20.00%
6 Months
23.02%
1 Year
46.06%
2 Year
53.99%
Key data
Stock price
$11.92
DAY RANGE
$8.14 - $11.69
52 WEEK RANGE
$6.55 - $16.19
52 WEEK CHANGE
$43.67
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Craig C. Parker
Region: US
Website: https://www.surrozen.com/
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.surrozen.com/
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Surrozen, Inc. discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Recent news